グラム陽性菌感染の世界市場

◆英語タイトル:Gram-positive Bacterial Infections Market (Drug Type - Antibiotic (B-Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols), Antifungal; Disease - MRSA, Pneumonia, Sepsis, Sinusitis, Cellulitis, Otitis, Pharyngitis, Impetigo; Route of Administration - Enteral, Parenteral; Distribution Channel - Hospital Pharmacies, Drug Stores and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
◆商品コード:TPM-C03067
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2019年2月
◆ページ数:225
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥637,450見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥967,450見積依頼/購入/質問フォーム
Global Site LicenseUSD11,795 ⇒換算¥1,297,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Researchが調査・発行した当レポートは、グラム陽性菌感染の世界市場について調べ、グラム陽性菌感染の世界規模、市場動向、市場環境、薬剤の種類別(抗生物質、抗真菌剤)分析、疾患別(MRSA、肺炎、敗血症、副鼻腔炎、蜂巣炎、中耳炎、咽頭炎、とびひ)分析、投与経路別(経腸、非経口)分析、流通経路別(院内薬局、ドラッグストア・小売薬局)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめました。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・グラム陽性菌感染の世界市場動向
・グラム陽性菌感染の世界市場環境
・グラム陽性菌感染の世界市場規模
・グラム陽性菌感染の世界市場規模:薬剤の種類別(抗生物質、抗真菌剤)
・グラム陽性菌感染の世界市場規模:疾患別(MRSA、肺炎、敗血症、副鼻腔炎、蜂巣炎、中耳炎、咽頭炎、とびひ)
・グラム陽性菌感染の世界市場規模:投与経路別(経腸、非経口)
・グラム陽性菌感染の世界市場規模:流通経路別(院内薬局、ドラッグストア・小売薬局)
・グラム陽性菌感染の世界市場:地域別市場規模・分析
・グラム陽性菌感染の北米市場規模・予測
・グラム陽性菌感染のアメリカ市場規模・予測
・グラム陽性菌感染の中南米市場規模・予測
・グラム陽性菌感染のヨーロッパ市場規模・予測
・グラム陽性菌感染のアジア市場規模・予測
・グラム陽性菌感染の日本市場規模・予測
・グラム陽性菌感染の中国市場規模・予測
・グラム陽性菌感染のインド市場規模・予測
・グラム陽性菌感染の中東市場規模・予測
・グラム陽性菌感染のアフリカ市場規模・予測
・競争状況・関連企業情報
【レポートの概要】

Gram-positive Bacterial Infections Market – Overview

Bacterial infections are a major cause of illness and are generally acquired through various sources. Based on staining, bacteria are classified into two types: gram-positive and gram-negative. Gram-positive bacteria retain gram stain and hence, are observed as violet purple colored stains when observed under the microscope. They are a major class of bacteria and cause various infections in humans. Gram-positive bacterial infections drugs act against gram-positive bacterial infections such as MRSA infections, sinusitis, cellulitis, and pneumonia. Antibiotics are widely used as the first line of treatment for these infections. Antibacterial resistance is considered to be a serious threat in this century for the treatment of bacterial infections. The market for gram-positive bacterial infections is expanding significantly due to a rise in the number of cases of bacterial infections and rapid increase in antibacterial resistance. Furthermore, infection control in healthcare settings and increasing government initiatives & funding for R&D activities have fuelled the gram-positive bacterial infections market.

The gram-positive bacterial infections market has been exclusively analyzed based on drug type, disease, route of administration, distribution channel, and region. Based on drug type, the global market has been divided into antibiotic, antifungal and others. The antibiotic segment has been further sub-segmented into B-Lactam, quinolones, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, and others. In terms of disease, the global gram-positive bacterial infections market has been segmented into MRSA, pneumonia, sepsis, sinusitis, cellulitis, otitis, pharyngitis, impetigo, and others. Based on route of administration, the global market has been classified into enteral, parenteral, and others. Based on distribution channel, the global gram-positive bacterial infections market has been split into hospital pharmacies, drug stores and retail pharmacies, and others. Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities and useful insights. The report gives current and future market size for each segment and sub segments for the period from 2018 to 2026 in terms of revenue in US$ Mn, considering 2017 as the base year. The compound annual growth rate (%CAGR) has been provided for each segment and market for the period of 2018 to 2026 with market size estimations.

In terms of region, the global market has been segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further sub-segmented into major countries and sub-regions. The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2016 to 2026, with their growth rate (%) for the period from 2018 to 2026. The study also offers a list of recommendations, highlights and some useful insights of the market which will surely help new companies willing to enter the market and for existing companies to increase market shares, which is likely to help in the decision-making process.

The market overview section of the report demonstrates the market dynamics and market trends such as drivers, restraints and opportunities that influence the current and future status of the gram-positive bacterial infections market. The report also covers market revenue projections, market attractiveness analysis and key market share analysis in the market overview section in order to provide a thorough analysis of the overall competitive scenario in the global gram-positive bacterial infections market.

The report concludes with the company profiles section that includes key information about the major players in the market. Key players identified in this report are Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithkline plc (GSK), Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, and Allergan plc. Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, Business segments and recent developments.

The global gram-positive bacterial infections market has been segmented as follows:

Global Gram-positive Bacterial Infections Market, by Drug Type

Antibiotic
B-lactam
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
Others
Antifungal
Others (Antitoxins, Corticosteroids, Supplements, Anti-Dialectic)
Global Gram-positive Bacterial Infections Market, by Disease

MRSA
Pneumonia
Sepsis
Sinusitis
Cellulitis
Otitis
Pharyngitis
Impetigo
Others (Anthrax, Erysipelothricosis, Necrotizing Fasciitis, Scarlet Fever, and Listeria)
Global Gram-positive Bacterial Infections Market, by Route of Administration

Enteral
Parenteral
Others (Topical, Transdermal)
Global Gram-positive Bacterial Infections Market, by Distribution Channel

Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Others (Online Pharmacies, Mail Pharmacies, and Home Care Pharmacies)
Global Gram-positive Bacterial Infections Market, by Region

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of the Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

【レポートの目次】

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gram-positive Bacterial Infections Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Global Gram-positive Bacterial Infections Market Taxonomy
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gram-positive Bacterial Infections Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Patent Landscape
5.2. Key Success Factors of Top Players
5.3. Branded vs. Generic Drugs Overview

6. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
6.3.1. Antibiotic
6.3.1.1. B-Lactam
6.3.1.2. Quinolones
6.3.1.3. Macrolides
6.3.1.4. Tetracyclines
6.3.1.5. Aminoglycosides
6.3.1.6. Sulfonamides
6.3.1.7. Phenicols
6.3.1.8. Others
6.3.2. Antifungal
6.3.3. Others
6.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type

7. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Disease
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
7.3.1. MRSA
7.3.2. Pneumonia
7.3.3. Sepsis
7.3.4. Sinusitis
7.3.5. Cellulitis
7.3.6. Otitis
7.3.7. Pharyngitis
7.3.8. Impetigo
7.3.9. Others
7.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type

8. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
8.3.1. Enteral
8.3.2. Parenteral
8.3.3. Others
8.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration

9. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospital Pharmacies
9.3.2. Drug Stores and Retail Pharmacies
9.3.3. Others
9.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel

10. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Gram-positive Bacterial Infections Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Gram-positive Bacterial Infections Market Attractiveness, by Region

11. North America Gram-positive Bacterial Infections Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
11.2.1. Antibiotic
11.2.1.1. B-Lactam
11.2.1.2. Quinolones
11.2.1.3. Macrolides
11.2.1.4. Tetracyclines
11.2.1.5. Aminoglycosides
11.2.1.6. Sulfonamides
11.2.1.7. Phenicols
11.2.1.8. Others
11.2.2. Antifungal
11.2.3. Others
11.3. North America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
11.3.1. MRSA
11.3.2. Pneumonia
11.3.3. Sepsis
11.3.4. Sinusitis
11.3.5. Cellulitis
11.3.6. Otitis
11.3.7. Pharyngitis
11.3.8. Impetigo
11.3.9. Others
11.4. North America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
11.4.1. Enteral
11.4.2. Parenteral
11.4.3. Others
11.5. North America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
11.5.1. Hospital Pharmacies
11.5.2. Drug Stores and Retail Pharmacies
11.5.3. Others
11.6. North America Gram-positive Bacterial Infections Market Value Forecast, by Country, 2016–2026
11.6.1. U.S.
11.6.2. Canada
11.7. North America Gram-positive Bacterial Infections Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Disease
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country

12. Europe Gram-positive Bacterial Infections Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
12.2.1. Antibiotic
12.2.1.1. B-Lactam
12.2.1.2. Quinolones
12.2.1.3. Macrolides
12.2.1.4. Tetracyclines
12.2.1.5. Aminoglycosides
12.2.1.6. Sulfonamides
12.2.1.7. Phenicols
12.2.1.8. Others
12.2.2. Antifungal
12.2.3. Others
12.3. Europe Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
12.3.1. MRSA
12.3.2. Pneumonia
12.3.3. Sepsis
12.3.4. Sinusitis
12.3.5. Cellulitis
12.3.6. Otitis
12.3.7. Pharyngitis
12.3.8. Impetigo
12.3.9. Others
12.4. Europe Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
12.4.1. Enteral
12.4.2. Parenteral
12.4.3. Others
12.5. Europe Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
12.5.1. Hospital Pharmacies
12.5.2. Drug Stores and Retail Pharmacies
12.5.3. Others
12.6. Europe Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Europe Gram-positive Bacterial Infections Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Disease
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region

13. Asia Pacific Gram-positive Bacterial Infections Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
13.2.1. Antibiotic
13.2.1.1. B-Lactam
13.2.1.2. Quinolones
13.2.1.3. Macrolides
13.2.1.4. Tetracyclines
13.2.1.5. Aminoglycosides
13.2.1.6. Sulfonamides
13.2.1.7. Phenicols
13.2.1.8. Others
13.2.2. Antifungal
13.2.3. Others
13.3. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
13.3.1. MRSA
13.3.2. Pneumonia
13.3.3. Sepsis
13.3.4. Sinusitis
13.3.5. Cellulitis
13.3.6. Otitis
13.3.7. Pharyngitis
13.3.8. Impetigo
13.3.9. Others
13.4. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
13.4.1. Enteral
13.4.2. Parenteral
13.4.3. Others
13.5. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
13.5.1. Hospital Pharmacies
13.5.2. Drug Stores and Retail Pharmacies
13.5.3. Others
13.6. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. Australia & New Zealand
13.6.5. Rest of APAC
13.7. Asia Pacific Gram-positive Bacterial Infections Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Disease
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region

14. Latin America Gram-positive Bacterial Infections Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type,2016–2026
14.2.1. Antibiotic
14.2.1.1. B-Lactam
14.2.1.2. Quinolones
14.2.1.3. Macrolides
14.2.1.4. Tetracyclines
14.2.1.5. Aminoglycosides
14.2.1.6. Sulfonamides
14.2.1.7. Phenicols
14.2.1.8. Others
14.2.2. Antifungal
14.2.3. Others
14.3. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
14.3.1. MRSA
14.3.2. Pneumonia
14.3.3. Sepsis
14.3.4. Sinusitis
14.3.5. Cellulitis
14.3.6. Otitis
14.3.7. Pharyngitis
14.3.8. Impetigo
14.3.9. Others
14.4. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
14.4.1. Enteral
14.4.2. Parenteral
14.4.3. Others
14.5. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
14.5.1. Hospital Pharmacies
14.5.2. Drug Stores and Retail Pharmacies
14.5.3. Others
14.6. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
14.6.1. Brazil
14.6.2.Mexico
14.6.3. Rest of LATAM
14.7. Latin America Gram-positive Bacterial Infections Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Disease
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region

15. Middle East & Africa Gram-positive Bacterial Infections Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
15.2.1. Antibiotic
15.2.1.1. B-Lactam
15.2.1.2. Quinolones
15.2.1.3. Macrolides
15.2.1.4. Tetracyclines
15.2.1.5. Aminoglycosides
15.2.1.6. Sulfonamides
15.2.1.7. Phenicols
15.2.1.8. Others
15.2.2. Antifungal
15.2.3. Others
15.3. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
15.3.1. MRSA
15.3.2. Pneumonia
15.3.3. Sepsis
15.3.4. Sinusitis
15.3.5. Cellulitis
15.3.6. Otitis
15.3.7. Pharyngitis
15.3.8. Impetigo
15.3.9. Others
15.4. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
15.4.1. Enteral
15.4.2. Parenteral
15.4.3. Others
15.5. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
15.5.1. Hospital Pharmacies
15.5.2. Drug Stores and Retail Pharmacies
15.5.3. Others
15.6. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
15.6.1. GCC Countries
15.6.2.South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Disease
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region

16. Competition Landscape
16.1. Market Player-Competition Matrix(By Tier and Size of companies)
16.2. Market Share Analysis By Tier and Size of the Company(2017)
16.3. Company Profiles
16.3.1. Bayer AG
16.3.2. Pfizer, Inc.
16.3.3. Sanofi
16.3.4. GlaxoSmithKline plc
16.3.5. Merck & Co., Inc.
16.3.6. AstraZeneca
16.3.7. Theravance Biopharma
16.3.8. Bristol-Myers Squibb Company
16.3.9. Novartis AG
16.3.10. Allergan plc.

List of Tables

Table 01: Recent Patents, Gram-Positive Bacterial Infection Drugs
Table 02: Branded Drug Patents and Generic Drugs Overview
Table 03: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
Table 04: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
Table 05: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
Table 06: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 07: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 09: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 10: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
Table 11: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
Table 12: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
Table 13: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 14: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 15: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 16: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
Table 17: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
Table 18: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
Table 19: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 20: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
Table 23: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
Table 24: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
Table 25: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 26: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 27: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 28: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
Table 29: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
Table 30: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
Table 31: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 32: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 33: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 34: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
Table 35: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
Table 36: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
Table 37: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 38: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Revenue Share, by Drug Type
Figure 03: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, 2016–2026
Figure 04: Global Gram-positive Bacterial Infections Market Value Share, by Drug Type (2017)
Figure 05: Global Gram-positive Bacterial Infections Market Value Share, by Disease (2017)
Figure 06: Global Gram-positive Bacterial Infections Market Value Share, by Route of Administration (2017)
Figure 07: Global Gram-positive Bacterial Infections Market Value Share, by Distribution Channel (2017)
Figure 08: Global Gram-positive Bacterial Infections Market Value Share, by Region (2017)
Figure 09: Number of Patent Applications, 2010-2018 (Based on Priority Year)
Figure 10: Patent Application, by Priority Country (2010-2018)
Figure 11: Contributions (%), from Key Applications- 2010 to 2018
Figure 12: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Drug Type, 2017 and 2026
Figure 13: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Antibiotic, 2016?2026
Figure 14: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Antifungal, 2016?2026
Figure 15: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
Figure 16: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Drug Type
Figure 17: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Disease, 2017 and 2026
Figure 18: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by MRSA, 2016–2026
Figure 19: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Pneumonia, 2016–2026
Figure 20: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Sepsis, 2016–2026
Figure 21: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Sinusitis, 2016–2026
Figure 22: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Cellulitis, 2016–2026
Figure 23: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Otitis, 2016–2026
Figure 24: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Pharyngitis, 2016–2026
Figure 25: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Impetigo, 2016–2026
Figure 26: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
Figure 27: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Disease
Figure 28: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Route of Administration, 2017 and 2026
Figure 29: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Enteral, 2016–2026
Figure 30: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2016–2026
Figure 31: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
Figure 32: Gram-positive Bacterial Infections Market Attractiveness Analysis, by Route of Administration
Figure 33: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 34: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 35: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Drug Stores and Retail Pharmacies, 2016–2026
Figure 36: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
Figure 37: Gram-positive Bacterial Infections Market Attractiveness Analysis, by Distribution Channel
Figure 38: Global Gram-positive Bacterial Infections Market Value Share, by Region, 2017 and 2026
Figure 39: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Region, 2018–2026
Figure 40: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 41: North America Gram-positive Bacterial Infections Market Value Share, by Country, 2017 and 2026
Figure 42: North America Gram-positive Bacterial Infections Market Attractiveness, by Country, 2017–2026
Figure 43: North America Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
Figure 44: North America Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
Figure 45: North America Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
Figure 46: North America Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
Figure 47: North America Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
Figure 48: North America Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
Figure 49: North America Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
Figure 50: North America Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
Figure 51: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 52: Europe Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 53: Europe Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 54: Europe Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
Figure 55: Europe Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
Figure 56: Europe Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
Figure 57: Europe Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
Figure 58: Europe Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
Figure 59: Europe Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
Figure 60: Europe Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
Figure 61: Europe Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
Figure 62: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 63: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 64: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 65: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
Figure 66: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
Figure 67: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
Figure 68: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
Figure 69: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
Figure 70: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
Figure 71: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
Figure 72: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
Figure 73: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 74: Latin America Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 75: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 76: Latin America Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
Figure 77: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
Figure 78: Latin America Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
Figure 79: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
Figure 80: Latin America Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
Figure 81: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
Figure 82: Latin America Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
Figure 83: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
Figure 84: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 85: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 86: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 87: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
Figure 88: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
Figure 89: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
Figure 90: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
Figure 91: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
Figure 92: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
Figure 93: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
Figure 94: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[グラム陽性菌感染の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆